On May 16, 2018 Indivior (INVVY) Was Downgraded To Neutral From Buy.

May 16, 2018 - By Mark Mitchell

Indivior PLC (OTCMKTS:INVVY) Corporate Logo

Citigroup Decreased Indivior (INVVY)’s Stock Rating to Neutral.

The rating downgrade of Indivior (INVVY) was issued on 15 May. Citigroup lowered the rating from Buy to Neutral.

INVVY is reaching $31.5225 during the last trading session, after increased 2.01%.Currently Indivior PLC is after 0.00% change in last May 16, 2017. INVVY has 2,637 shares volume. INVVY underperformed by 11.55% the S&P 500.

Indivior PLC, together with its subsidiaries, develops, makes, and sells buprenorphine prescription drugs for the treatment of opioid dependence.The company has $4.60 billion market cap. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia.The P/E ratio is 78.81. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.